Chaim Lebovits - 30 Sep 2024 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Signature
/s/ Chaim Lebovits
Issuer symbol
BCLI
Transactions as of
30 Sep 2024
Net transactions value
+$11,308
Form type
4
Filing time
02 Oct 2024, 08:00:14 UTC
Previous filing
31 Jul 2024
Next filing
03 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCLI Common Stock Purchase $5,016 +22,000 +1.9% $0.2280 1,186,865 30 Sep 2024 Direct F1
transaction BCLI Common Stock Purchase $6,292 +1,836 +2.3% $3.43* 80,960 01 Oct 2024 Direct F2, F3
holding BCLI Common Stock 133,389 30 Sep 2024 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.2258 to $0.2302, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
F2 Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.
F3 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.40 to $3.45, inclusive.
F4 Includes (i) 128,919 shares of Common Stock owned by ACCBT Corp. and (ii) 4,470 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.